Newly-diagnosed Pediatric T-cell ALL Protocol

This is a prospective, multicenter study conducted within the Chinese Children's Cancer Group (CCCG). The study aims to evaluate whether the addition of three novel agents, dasatinib, venetoclax and homoharringtonine, can improve the minimal residual disease (MRD)-negative remission rate, enhance event-free survival (EFS), and reduce the cumulative incidence of relapse (CIR) in pediatric patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL).

NCT Number	NCT06855810
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Enrollment	610 participants
Start Date	2025-03-11
Primary Completion	2030-06 (estimated)
Study Completion	2031-06 (estimated)
Updated on ClinicalTrials.gov	2025-08-26